Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.
OBJECTIVE
To Characterize a new human lung cancer cell line Am1010, derived from drug-surviving cells (DSCs).


METHODS
The Am1010 cell line was established after 4 cycles of chemotherapy from an arm muscle metastatic tumor of a patient diagnosed with lung adenocarcinoma. The cell line has been remained in continuous culture for more than one year during this study.


RESULTS
The Am1010 cell line demonstrated in vitro multi-drug-resistance to cisplatin, taxol, and gefitinib. The Am1010 cell doubling time without drug treatment was 42.395 h. The IC(50) value of cisplatin was 4.299 micromol/L and >10 micromol/L for the Am1010 and P0318 (a cell line derived from non-DSCs) cells, respectively. The IC(50) value of taxol was 0.067 micromol/L and >1 micromol/L for the Am1010 and P0318 cells, respectively. The IC(50) value of gefitinib was 15.233 micromol/L and >70 micromol/L for Am1010 and P0318 cells, respectively. 11 genes involved in the focal adhesion and cell adhesion pathways were found to be differentially expressed. The cells of Am1010 have a significantly larger chromosome number than most lung cancer cell lines.


CONCLUSIONS
This novel DSCs derived lung cancer cell line will be a valuable in vitro tool for the investigation of lung cancer drug resistance and metastasis.
Li
Hui-ling
HL
Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The 1st Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, China.
Xie
Si-ming
SM
Zhang
Liang
L
Cai
Cheng-jie
CJ
Wang
Wei
W
Huang
Jun
J
Wang
Dao-yuan
DY
Wen
Dan-ping
DP
Deng
Qiu-hua
QH
Zhong
Nan-shan
NS
He
Jian-xing
JX
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000818:Animals; D045744:Cell Line, Tumor / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation; D002875:Chromosomes / Q000235:genetics; D002945:Cisplatin / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D000077156:Gefitinib; D020869:Gene Expression Profiling; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*
D011799:Quinazolines; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib